Dataset Information

TMT quantitative proteomic analysis of craniopharyngioma tissues

ABSTRACT: Craniopharyngiomas are rare epithelial tumors derived from pituitary gland embryonic tissue. This epithelial tumor entity can be divided into the adamantinomatuous (ACP) and papillary (PCP) subtypes with the histomorphological and genetic differences. Genomic and transcriptomic profiles of craniopharyngiomas have been investigated, however the proteomic contribution to these profiles has yet to be elucidated. Recent improvement in high-throughput quantitative proteomic approaches have introduced new opportunities for a better understanding of these disease and an efficient discovering of biomarkers. In this study, we report a systems-level proteomic study of sub-type associated proteome changes in six specimens of ACP and five specimens of PCP using an integrated approach that combines mass spectrometry-based quantitative proteomics, statistical analysis, and bioinformatics analysis.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Neuron

DISEASE(S): Craniopharyngioma

SUBMITTER: Dohyun Han

LAB HEAD: Dohyun han

PROVIDER: PXD028790 | Pride | 2022-02-16

REPOSITORIES: Pride

ACCESS DATA

Publications

In-depth proteomic profiling captures subtype-specific features of craniopharyngiomas.

Kim Jung Hee JH Kim Hyeyoon H Dan Kisoon K Kim Seong-Ik SI Park Sung-Hye SH Han Dohyun D Kim Yong Hwy YH

Scientific reports 20211027 1

Craniopharyngiomas are rare epithelial tumors derived from pituitary gland embryonic tissue. This epithelial tumor can be categorized as an adamantinomatous craniopharyngioma (ACP) or papillary craniopharyngioma (PCP) subtype with histopathological and genetic differences. Genomic and transcriptomic profiles of craniopharyngiomas have been investigated; however, the proteomic profile has yet to be elucidated and added to these profiles. Recent improvements in high-throughput quantitative proteom ...[more]

PMID: 34707096

Similar Datasets

Project description:Introduction: Pediatric adamantinomatous craniopharyngioma (ACP) is a histologically benign but clinically aggressive brain tumor that arises from the sellar/suprasellar region. Despite a high survival rate with current surgical and radiation therapy (75-95% at 10 years), ACP is associated with debilitating visual, endocrine, neurocognitive and psychological morbidity, resulting in exceptionally poor quality of life for survivors. Identification of an effective pharmacological therapy would drastically decrease morbidity and improve long term outcomes for children with ACP. Results: Using microarray analysis of 15 ACP patient samples, we have found several pharmaceutical targets that are significantly and consistently overexpressed in our panel of ACP relative to other pediatric brain tumors, pituitary tumors, normal pituitary and normal brain tissue. Among the most highly expressed are several targets of the kinase inhibitor dasatinib -- LCK, EPHA2 and SRC; EGFR pathway targets -- AREG, EGFR and ERBB3; and other potentially actionable cancer targets -- SHH, MMP9 and MMP12. We confirm by Western blot that a subset of these targets is highly expressed in ACP primary tumor samples. Discussion: We report here the first microarray gene expression analysis for ACP and the identification of targets for rational therapy. Experimental drugs targeting each of these gene products are currently being tested clinically and pre-clinically for the treatment of other tumor types. This study provides a rationale for further pre-clinical and clinical studies of novel pharmacological treatments for ACP. Development of pre-clinical mouse and cell culture models for ACP will further enable the translation of these targets from the lab to the clinic. Gene expression profiles were generated from surgical tumor and normal brain samples (n=210) using Affymetrix HG-U133 Plus 2.0 chips. Gene expression profiles of adamantinomatous craniopharyngioma (ACP) were compared to a cohort of other tumor samples and normal brain tissues, and analyzed via gene set enrichment (GSEA analysis) and hierarchical clustering analysis to identify high expression of potential drug targets. The sample metadata and processed data for the complete dataset, which includes reanalysis of 23 Samples from GSE26966, 33 Samples from GSE35493, and 42 Samples from GSE50385, are linked below as supplementary files.

Dataset Information

TMT quantitative proteomic analysis of craniopharyngioma tissues

Publications

In-depth proteomic profiling captures subtype-specific features of craniopharyngiomas.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure